Cargando…
Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST
Natural killer (NK) cells are currently used in clinical trials to treat tumors. However, such therapies still suffer from problems such as donor variability, reproducibility, and more, which prevent a wider use of NK cells therapeutics. Here we show a potential immunotherapy combining NK cell-media...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440710/ https://www.ncbi.nlm.nih.gov/pubmed/37609636 http://dx.doi.org/10.1016/j.isci.2023.107284 |
_version_ | 1785093212198666240 |
---|---|
author | Kotzur, Rebecca Stein, Natan Kahlon, Shira Berhani, Orit Isaacson, Batya Mandelboim, Ofer |
author_facet | Kotzur, Rebecca Stein, Natan Kahlon, Shira Berhani, Orit Isaacson, Batya Mandelboim, Ofer |
author_sort | Kotzur, Rebecca |
collection | PubMed |
description | Natural killer (NK) cells are currently used in clinical trials to treat tumors. However, such therapies still suffer from problems such as donor variability, reproducibility, and more, which prevent a wider use of NK cells therapeutics. Here we show a potential immunotherapy combining NK cell-mediated tumor eradiation and long non-coding (lnc) RNAs. We overexpressed the interferon (IFN) [Formula: see text] secretion-enhancing lncRNA nettoie Salmonella pas Theiler’s (NeST) in the NK cell-like cell line YTS. YTS cells express the co-stimulatory receptor 2B4 whose main ligand is CD48. On YTS cells, 2B4 functions by direct activation. We showed that NeST overexpression in YTS cells resulted in increased IFN [Formula: see text] release upon interaction with CD48 (selectively enhanced (se)YTS cells). Following irradiation, the seYTS cells lost proliferation capacity but were still able to maintain their killing and IFN [Formula: see text] secretion capacities. Finally, we demonstrated that irradiated seYTS inhibit tumor growth in vivo. Thus, we propose seYTS cells as off-the-shelve therapy for CD48-expressing tumors. |
format | Online Article Text |
id | pubmed-10440710 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-104407102023-08-22 Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST Kotzur, Rebecca Stein, Natan Kahlon, Shira Berhani, Orit Isaacson, Batya Mandelboim, Ofer iScience Article Natural killer (NK) cells are currently used in clinical trials to treat tumors. However, such therapies still suffer from problems such as donor variability, reproducibility, and more, which prevent a wider use of NK cells therapeutics. Here we show a potential immunotherapy combining NK cell-mediated tumor eradiation and long non-coding (lnc) RNAs. We overexpressed the interferon (IFN) [Formula: see text] secretion-enhancing lncRNA nettoie Salmonella pas Theiler’s (NeST) in the NK cell-like cell line YTS. YTS cells express the co-stimulatory receptor 2B4 whose main ligand is CD48. On YTS cells, 2B4 functions by direct activation. We showed that NeST overexpression in YTS cells resulted in increased IFN [Formula: see text] release upon interaction with CD48 (selectively enhanced (se)YTS cells). Following irradiation, the seYTS cells lost proliferation capacity but were still able to maintain their killing and IFN [Formula: see text] secretion capacities. Finally, we demonstrated that irradiated seYTS inhibit tumor growth in vivo. Thus, we propose seYTS cells as off-the-shelve therapy for CD48-expressing tumors. Elsevier 2023-07-05 /pmc/articles/PMC10440710/ /pubmed/37609636 http://dx.doi.org/10.1016/j.isci.2023.107284 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kotzur, Rebecca Stein, Natan Kahlon, Shira Berhani, Orit Isaacson, Batya Mandelboim, Ofer Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST |
title | Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST |
title_full | Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST |
title_fullStr | Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST |
title_full_unstemmed | Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST |
title_short | Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST |
title_sort | eradication of cd48-positive tumors by selectively enhanced yts cells harnessing the lncrna nest |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440710/ https://www.ncbi.nlm.nih.gov/pubmed/37609636 http://dx.doi.org/10.1016/j.isci.2023.107284 |
work_keys_str_mv | AT kotzurrebecca eradicationofcd48positivetumorsbyselectivelyenhancedytscellsharnessingthelncrnanest AT steinnatan eradicationofcd48positivetumorsbyselectivelyenhancedytscellsharnessingthelncrnanest AT kahlonshira eradicationofcd48positivetumorsbyselectivelyenhancedytscellsharnessingthelncrnanest AT berhaniorit eradicationofcd48positivetumorsbyselectivelyenhancedytscellsharnessingthelncrnanest AT isaacsonbatya eradicationofcd48positivetumorsbyselectivelyenhancedytscellsharnessingthelncrnanest AT mandelboimofer eradicationofcd48positivetumorsbyselectivelyenhancedytscellsharnessingthelncrnanest |